Filtered By:
Cancer: Pancreatic Cancer
Therapy: Incretin Therapy

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 3 results found since Jan 2013.

Role of TREK-1 in Health and Disease, Focus on the Central Nervous System
Conclusion and Perspectives Since their cloning 20 years ago, the physiological importance of TREK-1 channels has continued to grow (Figure 3). Today, TREK-1 channels have been shown to be important and their presence is essential in a number of physiopathological processes. Their involvement in these different processes demonstrate the necessity to design pharmacological modulators, activators or inhibitors, of these channels to correct any TREK-1-related dysfunctions. Despites a number of studies and many molecule screenings, only few putative new drugs were identified. The activators belonging to the ML and BL series ...
Source: Frontiers in Pharmacology - April 10, 2019 Category: Drugs & Pharmacology Source Type: research

Diabetes drugs may be linked to pancreatic cancer
Conclusion This article presents important concerns that glucagon-like peptide-1 (GLP-1) agonists and dipeptidylpeptidase-4 (DPP-4) inhibitors could potentially increase the risk of inflammation and cancerous changes in the pancreas. The agencies that regulate medicines in Europe and the USA are aware of these issues, and told the BMJ that their analyses show increased reporting of pancreatic cancer among people taking these types of drugs. However, the agencies note that it has not been established whether these drugs directly cause the adverse effects seen in the pancreas. Both agencies are reviewing emerging eviden...
Source: NHS News Feed - June 10, 2013 Category: Consumer Health News Tags: Medication Diabetes QA articles Source Type: news

Structural Insight on GPR119 Agonist as Potential Therapy for Type II Diabetes: A Comprehensive Review
Mini Rev Med Chem. 2023 Mar 2. doi: 10.2174/1389557523666230302140658. Online ahead of print.ABSTRACTDiabetes Mellitus [DM] is a long-term metabolic condition that is characterized by excessive blood glucose. DM is the third most death-causing disease, leading to retinopathy, nephropathy, loss of vision, stroke, and cardiac arrest. Around 90% of the total cases of diabetic patients have Type II Diabetes Mellitus[T2DM]. Among various approaches for the treatment of T2DM. G protein-coupled receptors [GPCRs] 119 have been identified as a new pharmacological target. GPR119 is distributed preferentially in the pancreas β-cells...
Source: Cancer Control - March 2, 2023 Category: Cancer & Oncology Authors: Priyanshu Nema Vivek Asati Priyadarshi Kendya Twinkle Gupta Shivangi Agarwal Shivam Kori Varsha Kashaw Arun K Iyer Sushil Kumar Kashaw Source Type: research